Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase

Related Keywords

United States ,Paris ,France General ,France ,American ,Thomas Larsen ,Evan Berland ,Timothy Gilbert ,Dietmar Berger ,Nicolas Obrist ,Felix Lauscher ,Tarik Elgoutni ,Corentine Driancourt ,European Union ,Drug Administration ,Nasdaq ,American Society Of Clinical Oncology ,Global Head Of Development At Sanofi ,European Hematology Association ,World Health Organization ,Euronext ,Clinical Oncology ,Annual Meeting ,Priority Review ,Biologics License Application ,Medical Officer ,Global Head ,Hematology Association ,Nonproprietary Naming ,Biological Products Guidance ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Accessed March ,Ihr Portfolio ,